Wedbush Reiterates Outperform on Viridian Therapeutics, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has reiterated an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $37.
December 04, 2023 | 1:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico reaffirmed an Outperform rating on Viridian Therapeutics and kept the price target at $37.
The reiteration of an Outperform rating by a reputable analyst like Laura Chico from Wedbush is a positive signal for investors, suggesting that the firm believes VRDN's stock will perform well. The maintained price target of $37 indicates a continued optimistic outlook for the stock's future performance. This endorsement is likely to instill confidence among investors and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100